Skip to main content
SpringerLink
Log in

Evidence on the Impact of Pharmacogenetics to Treat and Manage Cardiovascular Diseases

  • Reference work entry
  • First Online:
Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy

  • 194 Accesses

Abstract

Cardiovascular diseases are the leading cause of morbidity and mortality worldwide. Effective medications for the treatment of cardiovascular diseases include antithrombotic drugs, antihypertensive drugs, and lipid-lowering drugs. However, drug response can vary across individuals because of various factors, particularly genetic factors may explain almost 40% of individual differences in drug response. This chapter summarizes pharmacogenetic studies of drugs for cardiovascular disease treatment and highlights genes that should be tested according to internationally recognized clinical guidelines and recommendations. Then based on evidence integrated from clinical studies and guidelines for these drugs, we illustrated the progress of pharmacogenetics research to clinical implementation. Overall, pharmacogenetic research of drugs for cardiovascular disease treatment is still accumulating, but pharmacogenetic testing is now available to guide the prescribing of metoprolol, clopidogrel, warfarin, rivaroxaban, and statins. As pharmacogenetic evidence increases, gene-guided drug treatments will help improve the quality of life and longevity of patients with cardiovascular diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 999.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 999.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Arnett DK, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the genetics of hypertension-associated treatment (GenHAT) study. Circulation. 2005;111(25):3374–83.

    Article  CAS  PubMed  Google Scholar 

  • Asiimwe IG, Zhang EJ, Osanlou R, Krause A, Dillon C, Suarez-Kurtz G, et al. Genetic factors influencing warfarin dose in black-African patients: a systematic review and meta-analysis. Clin Pharmacol Ther. 2020a;107(6):1420–33.

    Article  CAS  PubMed  Google Scholar 

  • Asiimwe IG, Zhang EJ, Osanlou R, Krause A, Dillon C, Suarez-Kurtz G, et al. Genetic factors influencing warfarin dose in black-African patients: a systematic review and meta-analysis. Clin Pharmacol Ther. 2020b;107(6):1420–33.

    Article  CAS  PubMed  Google Scholar 

  • Baudhuin LM, et al. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. Am J Cardiol. 2010;106(3):402–8.

    Article  CAS  PubMed  Google Scholar 

  • Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013;2013:464–70.

    Article  PubMed  Google Scholar 

  • Beitelshees AL, et al. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics. 2007;17(9):719–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Beitelshees AL, et al. CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet. 2009;2(4):362–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bhatnagar V, et al. G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am J Hypertens. 2009;22(3):332–8.

    Article  CAS  PubMed  Google Scholar 

  • Bhatnagar V, et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol. 2010;31(2):95–103.

    Google Scholar 

  • Bijl MJ, et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther. 2009;85(1):45–50.

    Article  CAS  PubMed  Google Scholar 

  • Biswas M, Rahaman S, Biswas TK, Ibrahim B. Effects of the ABCB1 C3435T single nucleotide polymorphism on major adverse cardiovascular events in acute coronary syndrome or coronary artery disease patients undergoing percutaneous coronary intervention and treated with clopidogrel: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(12):1605–16.

    Article  CAS  PubMed  Google Scholar 

  • Borre ED, Goode A, Raitz G, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost. 2018;118(12):2171–87.

    Google Scholar 

  • Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and Pharmacodynamic review. Clin Pharmacokinet. 2019;58(10):1265–79.

    Article  PubMed  PubMed Central  Google Scholar 

  • Cano-Corres R, Candás-Estébanez B, Padró-Miquel A, Fanlo-Maresma M, Pintó X, Alía-Ramos P. Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia. J Clin Lab Anal. 2018;32(8):e22566.

    Article  PubMed  PubMed Central  Google Scholar 

  • Chen J, Chen SY, Lian JJ, Zeng XQ, Luo TC. Pharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo-a systematic review. Clin Cardiol. 2013;36(4):184–9.

    Article  PubMed  PubMed Central  Google Scholar 

  • Chen L, et al. The association of ADRB1 and CYP2D6 polymorphisms with antihypertensive effects and analysis of their contribution to hypertension risk. Am J Med Sci. 2018a;355(3):235–9.

    Article  PubMed  Google Scholar 

  • Chen X, Jin DY, Stafford DW, Tie JK. Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu. Blood. 2018b;132(18):1974–84. https://doi.org/10.1182/blood-2018-05-846592. Epub 2018 Aug 8. PMID: 30089628; PMCID: PMC6213321

  • Chen C, Cao Y, Zheng Y, Dong Y, Ma J, Zhu W, Liu C. Effect of rivaroxaban or Apixaban in atrial fibrillation patients with stage 4-5 chronic kidney disease or on dialysis. Cardiovasc Drugs Ther. 2021;35(2):273–81.

    Article  PubMed  Google Scholar 

  • Cheung CC, Nattel S, Macle L, Andrade JG. Atrial fibrillation management in 2021: an updated comparison of the current CCS/CHRS, ESC, and AHA/ACC/HRS guidelines. Can J Cardiol. 2021; S0828-282X(21)00313–5.

    Google Scholar 

  • Chittani M, et al. TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. J Hypertens. 2015;33(6):1301–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Choi HD, et al. Effects of ACE and ADD1 gene polymorphisms on blood pressure response to hydrochlorothiazide: a meta-analysis. Int J Clin Pharmacol Ther. 2013;51(9):718–24.

    Article  CAS  PubMed  Google Scholar 

  • Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The clinical Pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin Pharmacol Ther. 2022;111(5):1007–21.

    Article  CAS  PubMed  Google Scholar 

  • CPIC’s levels for genes/drugs. CPIC®. https://cpicpgx.org/prioritization/#cpicLevels [May 23, 2021 @3:56 pm].

  • Cresci S, Depta JP, Lenzini PA, et al. Cytochrome P450 gene variants, race, and mortality among Clopidogrel treated patients following acute myocardial infarction. Circ Cardiovasc Genet. 2014;7(3):277–86.

    Google Scholar 

  • Cuevas A, Fernández C, Ferrada L, et al. HMGCR rs17671591 SNP determines lower plasma LDL-C after atorvastatin therapy in chilean individuals. Basic Clin Pharmacol Toxicol. 2016;118(4):292–7.

    Article  CAS  PubMed  Google Scholar 

  • D’Ascenzo F, Barbero U, Bisi M, et al. The prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysis. Biomed Res Int. 2014;2014:610296.

    Article  PubMed  PubMed Central  Google Scholar 

  • Daud ANA, Bergman JEH, Bakker MK, Wang H, Kerstjens-Frederikse WS, De Walle HEK, Groen H, Bos JHJ, Hak E, Wilffert B. P-glycoprotein-mediated drug interactions in pregnancy and changes in the risk of congenital anomalies: a case-reference study. Drug Saf. 2015;38:651–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost. 2006;32:003–15.

    Google Scholar 

  • Drugs@FDA: Drug Product Plavix (clopidogrel bisulfate), NDA020839, Rebel Distributors Corp. (n.d.-a.); URL: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event = overview.process&varApplNo = 020839

    Google Scholar 

  • Drugs@FDA: Drug Product ZOCOR (SIMVASTATIN), NDA019766, Merck Sharp & Dohme Corp. n.d.-b. URL: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event = overview.process&varApplNo = 019766

    Google Scholar 

  • Drugs@FDA: Drug Product ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM), NDA020702, Legacy Pharmaceutical Packaging, LLC. n.d.-c.URL: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event = overview.process&varApplNo = 020702

    Google Scholar 

  • Drugs@FDA: Drug Product CRESTOR (Rosuvastatin calcium), NDA021366, Carilion Materials Management. n.d.-d. URL: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event = overview.process&varApplNo = 021366

    Google Scholar 

  • Drugs@FDA: Drug Product PRAVACHOL (PRAVASTATIN SODIUM), NDA019898, E.R. Squibb & Sons, L.L.C. (n.d.-e). URL: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event = overview.process&varApplNo = 019898

    Google Scholar 

  • Duarte JD, Cavallari LH. Pharmacogenetics to guide cardiovascular drug therapy. Nat Rev Cardiol. 2021;

    Google Scholar 

  • Duarte JD, et al. Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression. Pharm J. 2013;13(3):257–63.

    CAS  Google Scholar 

  • Dutch Pharmacogenetics Working Group Guidelines. November 2018.; URL: https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf

  • Dutch Pharmacogenetics Working Group Guidelines August 2020. URL: https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2020.pdf

  • Fan X, et al. Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of captopril in women. Clin Pharmacol Ther. 2007;82(2):187–96.

    Article  CAS  PubMed  Google Scholar 

  • Filigheddu F, et al. Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension. Pharmacogenomics. 2010;11(3):319–25.

    Article  CAS  PubMed  Google Scholar 

  • Goldsack NR, Chambers RC, Dabbagh K, Laurent GJ. Molecules in focus thrombin. Int J Biochem Cell Biol. 1998;30:641–6.

    Article  CAS  PubMed  Google Scholar 

  • Gong Y, et al. Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet. 2012;5(6):686–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gong Y, et al. Pharmacogenomic genome-wide meta-analysis of blood pressure response to beta-blockers in hypertensive African Americans. Hypertension. 2016;67(3):556–63.

    Article  CAS  PubMed  Google Scholar 

  • Gosselin R, Grant RP, Adcock DM. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol. 2016;38:505–13.

    Article  CAS  PubMed  Google Scholar 

  • Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem JE, Narjoz C, Gaussem P, Beaune P, Funck-Brentano C, Azizi M, et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB 1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017;15:273–83.

    Article  CAS  PubMed  Google Scholar 

  • Haas S, Ten Cate H, Accetta G, et al. Quality of vitamin k antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the Garfield-af registry. PLoS One. 2016;11:e0164076.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hamadeh IS, et al. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. Clin Pharmacol Ther. 2014;96(2):175–81.

    Article  CAS  PubMed  Google Scholar 

  • Hammoudeh AJ, Khader Y, Kadri N, Al-Mousa E, Badaineh Y, Habahbeh L, Tabbalat R, Janabi H, Alhaddad IA. Adherence to the 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline on the use of Oral anticoagulant agents in middle eastern patients with atrial fibrillation: the Jordan atrial fibrillation (JoFib) study. Int J Vasc Med. 2021;2021:5515089.

    PubMed  PubMed Central  Google Scholar 

  • Hamrefors V, et al. Pharmacogenetic implications for eight common blood pressure-associated single-nucleotide polymorphisms. J Hypertens. 2012;30(6):1151–60.

    Article  CAS  PubMed  Google Scholar 

  • Hankey GJ, Eikelboom JW. Dabigatran Etexilate: a new oral thrombin inhibitor. Circulation. 2011;123:1436–50.

    Article  PubMed  Google Scholar 

  • He F, et al. The KCNH2 genetic polymorphism (1956, C>T) is a novel biomarker that is associated with CCB and alpha,beta-ADR blocker response in EH patients in China. PLoS One. 2013;8(4):e61317.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Heidari F, et al. Association of insertion/deletion polymorphism of angiotensin-converting enzyme gene among Malay male hypertensive subjects in response to ACE inhibitors. J Renin-Angiotensin-Aldosterone Syst. 2015;16(4):872–9.

    Article  CAS  PubMed  Google Scholar 

  • Hiltunen TP, et al. Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J Am Heart Assoc. 2015;4(1):e001521.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ho-Sook Kim HS, LimYH OMK, et al. The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes. Br J Clin Pharmacol. 2016;81(2):301–12.

    Article  PubMed  Google Scholar 

  • Hua S, Ma C, Zhang J, et al. Influence of APOA5 locus on the treatment efficacy of three statins: evidence from a randomized pilot study in Chinese subjects. Front Pharmacol. 2018;9:352.

    Article  PubMed  PubMed Central  Google Scholar 

  • Huang Y, et al. CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation. Int J Clin Pharmacol Ther. 2017;55(2):109–18.

    Article  CAS  PubMed  Google Scholar 

  • Ibrahim H, Kleiman N. Platelet pathophysiology, pharmacology, and function in coronary artery disease. Coron Artery Dis. 2017;28(7):614–23.

    Article  PubMed  Google Scholar 

  • Ing LK, Daali Y, Fontana P, et al. Rivaroxaban-induced hemorrhage associated with ABCB1 genetic defect. Front Pharmacol. 2016;7:494.

    Google Scholar 

  • Ing Lorenzini K, Daali Y, Fontana P, Desmeules J, Samer C. Rivaroxaban-induced hemorrhage associated with ABCB1 genetic defect. Front Pharmacol. 2016;7:494.

    Article  PubMed  PubMed Central  Google Scholar 

  • January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104–32.

    Article  PubMed  Google Scholar 

  • Jefferson BK, Foster JH, McCarthy JJ, et al. Aspirin resistance and a single gene. Am J Cardiol. 2005;95(6):805–8.

    Article  CAS  PubMed  Google Scholar 

  • Ji X, et al. Associations between human aldosterone synthase CYP11B2(−344T/C) gene polymorphism and antihypertensive response to valsartan in Chinese patients with essential hypertension. Int J Clin Exp Med. 2015;8(1):1173–7.

    PubMed  PubMed Central  Google Scholar 

  • Kalpana SR, Bharath G, Manjunath CN, Christopher R. Influence of VKORC1 and CYP2C9 polymorphisms on daily Acenocoumarol dose requirement in south Indian patients with mechanical heart valves. Clin Appl Thromb Hemost. 2017a;23(7):876–82. https://doi.org/10.1177/1076029616655617.

    Article  CAS  PubMed  Google Scholar 

  • Kalpana SR, Bharath G, Manjunath CN, Christopher R. Influence of VKORC1 and CYP2C9 polymorphisms on daily Acenocoumarol dose requirement in south Indian patients with mechanical heart valves. Clin Appl Thromb Hemost. 2017b Oct;23(7):876–82. https://doi.org/10.1177/1076029616655617.

    Article  CAS  PubMed  Google Scholar 

  • Kelley EF, et al. Economic evaluation of a pharmacogenomic multi-gene panel test to optimize anti-hypertension therapy: simulation study. J Med Econ. 2018;21(12):1246–53.

    Article  PubMed  Google Scholar 

  • Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet. 2017;18:331–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kim YA, Gosselin R, Van Cott EM. The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays. Int J Lab Hematol. 2015;37:e81–4.

    Article  CAS  PubMed  Google Scholar 

  • Konoshita T, I. Genomic Disease Outcome Consortium Study. Do genetic variants of the renin-angiotensin system predict blood pressure response to renin-angiotensin system-blocking drugs?: a systematic review of pharmacogenomics in the renin-angiotensin system. Curr Hypertens Rep. 2011;13(5):356–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Konoshita T, et al. Genetic variant of the renin-angiotensin system and diabetes influences blood pressure response to angiotensin receptor blockers. Diabetes Care. 2009;32(8):1485–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kurland L, et al. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) trial. Am J Hypertens. 2002;15(5):389–93.

    Article  CAS  PubMed  Google Scholar 

  • Lacut K, Ayme-Dietrich E, Gourhant L, Poulhazan E, Andro M, Becquemont L, Mottier D, Le Gal G, Verstuyft C. Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione. Br J Clin Pharmacol. 2012;73(3):428–36. https://doi.org/10.1111/j.1365-2125.2011.04095.x.

  • Lamoureux F, Duflot T. French network of Pharmacogenetics (RNPGX). Pharmacogenetics in cardiovascular diseases: state of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx). Therapie. 2017a;72(2):257–67.

    Google Scholar 

  • Lamoureux F, Duflot T. French network of Pharmacogenetics (RNPGX). Pharmacogenetics in cardiovascular diseases: state of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx). Therapie. 2017b;72(2):257–67.

    Article  PubMed  Google Scholar 

  • Langaee TY, et al. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther. 2007;81(3):386–91.

    Article  CAS  PubMed  Google Scholar 

  • Lefebvre J, et al. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol. 2007;63(5):575–82.

    Article  CAS  PubMed  Google Scholar 

  • Lepantalo A, Mikkelsson J, Res endiz JC, et al. Polymorphisms of COX-1 and GP VI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost. 2006;95(02):253–9.

    Article  CAS  PubMed  Google Scholar 

  • Lewis JP, Ryan K, O'Connell JR, et al. Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet. 2013;6(2):184–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li Y, Tang HL, Hu YF, Xie HG. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost. 2012;10(2):199–206.

    Google Scholar 

  • Li JX, Kim MH, Guo LZ, et al. Impact of CYP2C19 polymorphism on antiplatelet potency of Prasugrel 5 and 10 mg daily maintenance. Cardiology. 2018;140(3):155–62.

    Article  CAS  PubMed  Google Scholar 

  • Liu MY, Fan FF, Zhang Y, Li JP. The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2021;77(3):349–57.

    Article  CAS  PubMed  Google Scholar 

  • Lordkipanidze M, Diodati JG, Palisaitis DA, Schampaert E, Turgeon J, Pharand C. Genetic determinants of response to aspirin: appraisal of 4 candidate genes. Thromb Res. 2011;128(1):47–53.

    Article  CAS  PubMed  Google Scholar 

  • Luo JQ, et al. Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment. Pharmacogenomics. 2014;15(2):201–8.

    Article  CAS  PubMed  Google Scholar 

  • Luo JQ, et al. SLCO1B1 variants and angiotensin converting enzyme inhibitor (Enalapril)-induced cough: a pharmacogenetic study. Sci Rep. 2015;5:17253.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Magvanjav O, et al. Pharmacogenetic associations of beta1-adrenergic receptor polymorphisms with cardiovascular outcomes in the SPS3 trial (secondary prevention of small subcortical strokes). Stroke. 2017;48(5):1337–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mangravite LM, Medina MW, Cui JR, et al. Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Arterioscler Thromb Vasc Biol. 2010;30(7):1485–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • McDonough CW, et al. Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J Hypertens. 2013;31(4):698–704.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • McGrath ER, Kapral MK, Fang J, et al. Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology. 2013;81:825–32.

    Article  PubMed  Google Scholar 

  • Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009a;119(19):2553–60.

    Article  CAS  PubMed  Google Scholar 

  • Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MS. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol. 2009b;29(9):1310–5.

    Article  CAS  PubMed  Google Scholar 

  • Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010a;304(16):1821–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010b;376(9749):1312–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mega JL, Close SL, Wiviott SD, et al. PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. J Thromb Thrombolysis. 2016;41(3):374–83.

    Article  CAS  PubMed  Google Scholar 

  • Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967–77.

    Article  PubMed  PubMed Central  Google Scholar 

  • Meloche M, et al. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: a systematic review and meta-analysis. Br J Clin Pharmacol. 2020;86(6):1015–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Merali Z, Ross S, Paré G. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug Metabol Drug Interact. 2014a;29(3):143–51.

    Article  CAS  PubMed  Google Scholar 

  • Merali Z, Ross S, Paré G. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug Metabol Drug Interact. 2014b;29:143–51.

    Article  CAS  PubMed  Google Scholar 

  • Mosley JD, et al. A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough. Pharm J. 2016;16(3):231–7.

    CAS  Google Scholar 

  • Nakagawa J, Kinjo T, Iizuka M, Ueno K, Tomita H, Niioka T. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation. Basic Clin Pharmacol Toxicol. 2021;128(2):297–304.

    Article  CAS  PubMed  Google Scholar 

  • Nardin M, Verdoia M, Pergolini P, et al. Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients. Pharmacol Res. 2018;129:27–33.

    Article  CAS  PubMed  Google Scholar 

  • Nedios S. Screening for atrial fibrillation: does cardiovascular disease reduce the probability of detection? Int J Cardiol. 2021;S0167-5273(21):01097–4.

    Google Scholar 

  • Niu Y, et al. Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic substudy (INVEST-GENES). Circ Cardiovasc Genet. 2010;3(6):548–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • O’connor CT, Kiernan TJ, Yan BP. The genetic basis of antiplatelet and anticoagulant therapy: a pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagu lants (dabigatran, rivaroxaban, apixaban and édoxaban) expert Opin. Drug Metab Toxicol. 2017;13:725–39.

    Google Scholar 

  • Ohmichi N, et al. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am J Hypertens. 1997;10(8):951–5.

    Article  CAS  PubMed  Google Scholar 

  • Oliveira-Paula GH, et al. Pharmacogenomics and hypertension: current insights. Pharmgenomics Pers Med. 2019;12:341–59.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ortlepp JR, et al. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol. 2002;445(1–2):151–2.

    Article  CAS  PubMed  Google Scholar 

  • Pacanowski MA, et al. Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther. 2008;84(6):715–21.

    Article  CAS  PubMed  Google Scholar 

  • Padmanabhan S, Caulfield M, Dominiczak AF. Genetic and molecular aspects of hypertension. Circ Res. 2015;116(6):937–59.

    Article  CAS  PubMed  Google Scholar 

  • Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee M. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. J Am Heart Assoc. 2017; 6(7, article e005835).

    Google Scholar 

  • Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist Oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet. 2016;55:641–55. https://doi.org/10.1007/s40262-015-0342-7.

  • Paré G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127:1404–12.

    Article  PubMed  Google Scholar 

  • Pare G, et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2013;23(9):470–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Park JS, Cha KS, Lee HW, et al. Platelet reactivity and clinical outcomes in patients using CYP3A4-metabolized statins with clopidogrel in percutaneous coronary intervention. Heart Vessel. 2017;32(6):690–9.

    Article  Google Scholar 

  • Peng W, Shi X, Xu X, Yang L. Both CYP2C19 and PON1 Q192R genotypes influence platelet response to Clopidogrel by Thrombelastography in patients with acute coronary syndrome. Cardiovasc Ther. 2019;2019:3470145.

    Article  PubMed  PubMed Central  Google Scholar 

  • Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol. 2010;30(3):376–81.

    Article  CAS  PubMed  Google Scholar 

  • Phan L, Jin Y, Zhang H, Qiang W, Shekhtman E, Shao D, Revoe D, Villamarin R, Ivanchenko E, Kimura M, Wang ZY, Hao L, Sharopova N, Bihan M, Sturcke A, Lee M, Popova N, Wu W, Bastiani C, Ward M, Holmes JB, Lyoshin V, Kaur K, Moyer E, Feolo M, Kattman BL. ALFA: allele frequency aggregator. National Center for Biotechnology Information, U.S. National Library of Medicine 2020; Available from: www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa/

  • Pirmohamed M. Pharmacogenetics: past, present and future. Drug Discov Today. 2011 Oct;16(19–20):852–61.

    Article  CAS  PubMed  Google Scholar 

  • Pink J, Pirmohamed M, Lane S, Hughes DA. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Clin Pharmacol Ther. 2014;95(2):199–207.

    Article  CAS  PubMed  Google Scholar 

  • Plavix| European Medicines Agency. n.d.. URL: https://www.ema.europa.eu/en/medicines/human/EPAR/plavix

  • Poulussen FCP, et al. The effect of the CYP2D6 genotype on the maintenance dose of metoprolol in a chronic Dutch patient population. Pharmacogenet Genomics. 2019;29(7):179–82.

    Article  CAS  PubMed  Google Scholar 

  • Ramsey LB, Johnson SG, Caudle KE, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014;96(4):423–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Relling MV, Klein TE. CPIC: clinical Pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011;89(3):464–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rimpelä JM, et al. Replicated evidence for aminoacylase 3 and nephrin gene variations to predict antihypertensive drug responses. Pharmacogenomics. 2017;18(5):445–58.

    Article  PubMed  Google Scholar 

  • Roger VL, Sidney S, Fairchild AL, et al. Recommendations for cardiovascular health and disease surveillance for 2030 and beyond a policy statement from the American Heart Association. Circulation. 2020;141(9):e104–19.

    Article  PubMed  Google Scholar 

  • Rysz J, et al. Pharmacogenomics of hypertension treatment. Int J Mol Sci. 2020;21(13)

    Google Scholar 

  • Satoh T, Hosokawa M. Structure, function and regulation of carboxylesterases. Chem Int. 2006;162:195–211.

    CAS  Google Scholar 

  • Savinova AV, Shnayder NA, Petrova MM, Nasyrova RF. Promising areas of research on the pharmacogenetics of dabigatran etexilate. Pharmacokinet Pharm. 2020;1:35–41.

    Google Scholar 

  • Scott SA, Sangkuhl K, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schelleman H, et al. The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure. Eur J Hum Genet. 2006;14(7):860–6.

    Article  CAS  PubMed  Google Scholar 

  • Sehrt D, et al. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics. 2011;12(6):783–95.

    Article  CAS  PubMed  Google Scholar 

  • Sharp CF, et al. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure. Pharm J. 2009;9(3):175–84.

    CAS  Google Scholar 

  • Shi J, Wang X, Nguyen J-H, et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol. 2016a;119:76–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shi J, Wang X, Nguyen JH, Bleske BE, Liang Y, Liu L, Zhu HJ. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol. 2016b;119:76–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shnayder NA, Petrova MM, Shesternya PA, Savinova AV, Bochanova EN, Zimnitskaya OV, Pozhilenkova EA, Nasyrova RF. Using Pharmacogenetics of direct Oral anticoagulants to predict changes in their pharmacokinetics and the risk of adverse drug reactions. Biomedicine. 2021;9(5):451.

    CAS  Google Scholar 

  • Si D, et al. Association of common polymorphisms in β1-adrenergic receptor with antihypertensive response to carvedilol. J Cardiovasc Pharmacol. 2014;64(4):306–9.

    Article  CAS  PubMed  Google Scholar 

  • Singh S, et al. Genome-wide meta-analysis of blood pressure response to beta1-blockers: results from ICAPS (international consortium of antihypertensive pharmacogenomics studies). J Am Heart Assoc. 2019a;8(16):e013115.

    Article  PubMed  PubMed Central  Google Scholar 

  • Singh S, et al. Genomic association analysis reveals variants associated with blood pressure response to Beta-blockers in European Americans. Clin Transl Sci. 2019b;12(5):497–504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sridharan K, Sivaramakrishnan G. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional. J Clin Pharm Ther. 2020;

    Google Scholar 

  • Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist Oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–93. https://doi.org/10.1093/eurheartj/ehy136.

    Article  CAS  PubMed  Google Scholar 

  • Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007a;64:292–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007b;64:292–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stavroulakis GA, et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther. 2000;14(4):427–32.

    Article  CAS  PubMed  Google Scholar 

  • Storey RF, Melissa Thornton S, Lawrance R, et al. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets. 2009;20(5):341–8.

    Article  CAS  PubMed  Google Scholar 

  • Su X, Yan B, Wang L, et al. Oral anticoagulant agents in patients with atrial fibrillation and CKD: a systematic review and pairwise network meta-analysis. Am J Kidney Dis. 2021;S0272-6386(21):00530–8.

    Google Scholar 

  • Sun X, Yu WY, Ma WL, Huang LH, Yang GP. Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: a systematic review and meta-analysis. Biomed Rep. 2016;4(4):498–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Su X, et al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation. 2007;115(6):725–32.

    Article  CAS  PubMed  Google Scholar 

  • Su J, Xu H, Yang J, et al. ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis. Lipids Health Dis. 2015;14:122.

    Article  PubMed  PubMed Central  Google Scholar 

  • Svensson-Färbom P, et al. A functional variant of the NEDD4L gene is associated with beneficial treatment response with β-blockers and diuretics in hypertensive patients. J Hypertens. 2011;29(2):388–95.

    Article  PubMed  Google Scholar 

  • Swissmedic label for Simvastatin und Ezetimib. n.d.. URL: https://amiko.oddb.org/de/fi?gtin = 56953

    Google Scholar 

  • Swissmedic label for Triveram. n.d.. URL: https://amiko.oddb.org/de/fi?gtin = 65514

    Google Scholar 

  • Swissmedic label for rosuvastatin. n.d.. URL: https://amiko.oddb.org/de/fi?gtin = 56139

    Google Scholar 

  • Swissmedic label for pitavastatin. (n.d.). URL: https://amiko.oddb.org/de/fi?gtin = 62329

    Google Scholar 

  • Swissmedic label for Thrombozytenaggregationshemmer, exkl. Heparin (DuoPlavin 75/100 mg). (n.d.). URL: https://amiko.oddb.org/de/fi?gtin = 58696

  • Takeuchi M, Kobayashi T, Biss T, et al. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis. Pharm J. 2020;20(2):306–19.

    CAS  Google Scholar 

  • Tatarunas V, Kupstyte N, Zaliunas R, Giedraitiene A, Lesauskaite V. The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy. Pharmacogenomics. 2017;18(10):969–79.

    Article  CAS  PubMed  Google Scholar 

  • Tatarunas V, Nora Kupstyte-Kristapone NK, Norvilaite R, et al. The impact of CYP2C19 and CYP4F2 variants and clinical factors on treatment outcomes during antiplatelet therapy. Pharmacogenomics. 2019;20(7):483–92.

    Article  CAS  PubMed  Google Scholar 

  • Tang W, Shi QP, Ding F, Yu ML, Hua J, Wang YX. Impact of VKORC1 gene polymorphisms on warfarin maintenance dosage: a novel systematic review and meta-analysis of 53 studies. Int J Clin Pharmacol Ther. 2017;55(4):304–21.

    Article  CAS  PubMed  Google Scholar 

  • Thomas KL, Jackson LR, 2nd, Shrader P, et al. Prevalence, characteristics, and outcomes of valvular heart disease in patients with atrial fibrillation: insights from the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation). J Am Heart Assoc. 2017; 6(12, article e006475).

    Google Scholar 

  • Tomek A, Růžičková T, Kaplan V, Lacinová Z, Kumstýřová S, Šrámek M, Olšerová A, Janský P, Kolářová T, Neumann J, Schwabová JP, Maťoška V. Pharmacogenetic algorithm for predicting daily dose of warfarin in Caucasian patients of Czech origin. Drug Metab Pers Ther. 2020.

    Google Scholar 

  • Tomlinson B, Hu M, Lee VW, et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to Rosuvastatin. Clin Pharmacol Ther. 2010;87(5):558–62.

    Article  CAS  PubMed  Google Scholar 

  • Thompson JF, Hyde CL, Wood LS, et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the treating to new targets (TNT) cohort. Circ Cardiovasc Genet. 2009;2(2):173–81.

    Article  CAS  PubMed  Google Scholar 

  • Tian L, Zhang J, Xiao S, Huang J, Zhang Y, Shen J. Impact of polymorphisms of the GGCX gene on maintenance warfarin dose in Chinese populations: systematic review and meta-analysis. Meta Gene. 2015;5:43–54.

    Article  PubMed  PubMed Central  Google Scholar 

  • Timur AA, Murugesan G, Zhang L, et al. P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease. Int J Lab Hematol. 2012;34(5):473–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tse G, Gong M, Li G, Wong SH, Wu WKK, Wong WT, et al. Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2018;84(9):1868–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Turner ST, et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension. 2008;52(2):359–65.

    Article  CAS  PubMed  Google Scholar 

  • Turner ST, et al. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension. 2001;37(2 Pt 2):739–43.

    Article  CAS  PubMed  Google Scholar 

  • Turner ST, et al. Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension. 2013;62(2):391–7.

    Article  CAS  PubMed  Google Scholar 

  • Turner ST, et al. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension. 2012;59(6):1204–11.

    Article  CAS  PubMed  Google Scholar 

  • Unger T, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334–57.

    Article  CAS  PubMed  Google Scholar 

  • van den Ham HA, Souverein PC, Klungel OH, et al. Major bleeding in users of direct oral anticoagulants in atrial fibrillation: a pooled analysis of results from multiple population-based cohort studies. Pharmacoepidemiol Drug Saf. 2021;

    Google Scholar 

  • Vandell AG, et al. G protein receptor kinase 4 polymorphisms: beta-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension. 2012;60(4):957–64.

    Article  CAS  PubMed  Google Scholar 

  • Varenhorst C, Eriksson N, Johansson Å, et al. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015;36(29):1901–12.

    Article  CAS  PubMed  Google Scholar 

  • Verdoia M, Daffara V, Pergolini P, et al. Vitamin D binding protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Vasc Pharmacol. 2017;93-95:42–7.

    Article  CAS  Google Scholar 

  • Verdoia M, Tonon F, Gioscia R, et al. Impact of the rs73598374 polymorphism of the adenosine deaminase gene on platelet reactivity and long-term outcomes among patients with acute coronary syndrome treated with ticagrelor. Thromb Res. 2020;196:231–7.

    Article  CAS  PubMed  Google Scholar 

  • Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364(12):1144–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang ZQ, Zhang R, Zhang PP, Liu XH, Sun J, Wang J, et al. Pharmacogenetics-based warfarin dosing algorithm decreases time to stable anticoagulation and the risk of major hemorrhage: an updated meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2015;65(4):364–70.

    Article  CAS  PubMed  Google Scholar 

  • Wang J, Liu J, Zhou YQ, et al. Association among PlA1/A2 gene polymorphism, laboratory aspirin resistance and clinical outcomes in patients with coronary artery disease: an updated meta-analysis. Sci Rep. 2019a;9(1):13177.

    Article  PubMed  PubMed Central  Google Scholar 

  • Wang F, Guo J, Zhang A. Efficacy and safety of genotype-guided warfarin dosing in the Chinese population: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2019b;73(3):127–35.

    Article  CAS  PubMed  Google Scholar 

  • Warlo EMK, Arnesen H, Seljeflot I. A brief review on resistance to P2Y(12) receptor antagonism in coronary artery disease. Thromb J. 2019;20(17):11.

    Article  Google Scholar 

  • Weng Z, Li X, Li Y, Lin J, Peng F, Niu W. The association of four common polymorphisms from four candidate genes (COX-1, COX-2,ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. PLoS One. 2013;8(11):e78093.

    Article  PubMed  PubMed Central  Google Scholar 

  • Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2018;71(6):e13–e115.

    CAS  PubMed  Google Scholar 

  • Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE. Pharmacogenomics knowledge for personalized medicine. Clini Pharmacol Therap. 2012;92(4):414–7.

    Article  CAS  Google Scholar 

  • Woodard-Grice AV, et al. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2010;20(9):532–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wurtz M, Lordkipanidze M, Grove E. Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists. J Thromb Haemost. 2013;11(9):1627–39.

    Article  CAS  PubMed  Google Scholar 

  • Xiang Q, Zhang XD, Mu GY, et al. Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis. Eur J Clin Pharmacol. 2021;77(4):569–81.

    Google Scholar 

  • Xiao FY, Luo JQ, Liu M, et al. Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients. Sci Rep. 2017;7(1):7244.

    Google Scholar 

  • Xu K, Ye S, Zhang S, et al. Impact of platelet endothelial aggregation Receptor-1 genotypes on platelet reactivity and early cardiovascular outcomes in patients undergoing percutaneous coronary intervention and treated with aspirin and Clopidogrel. Circ Cardiovasc Interv. 2019;12(5):e007019.

    Article  CAS  PubMed  Google Scholar 

  • Yang T, Zhou Y, Chen C, Lu M, Ma L, Cui Y. Genotype-guided dosing versus conventional dosing of warfarin: a meta-analysis of 15 randomized controlled trials. J Clin Pharm Ther. 2019a;44(2):197–208.

    Article  CAS  PubMed  Google Scholar 

  • Yang T, Zhou Y, Chen C, Lu M, Ma L, Cui Y. Genotype-guided dosing versus conventional dosing of warfarin: a meta-analysis of 15 randomized controlled trials. J Clin Pharm Ther. 2019b;44(2):197–208.

    Article  CAS  PubMed  Google Scholar 

  • Yuan D, Shi X, Guo L, et al. Lower platelet aggregation is a risk factor for dual antiplatelet therapy-associated bleeding: a preliminary retrospective study with genotype analysis. Med Sci Monit. 2020;26:e923758.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang J, Chen Z, Chen C. Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: a systematic review and meta-analysis. Meta Gene. 2016a;9:197–209.

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhang J, Chen Z, Chen C. Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: a systematic review and meta-analysis. Meta Gene. 2016b;9:197–209.

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhang H, et al. Novel genes affecting blood pressure detected via gene-based association. Analysis G3 (Bethesda). 2015;5(6):1035–42.

    Article  CAS  PubMed  Google Scholar 

  • Zhang J, Tian L, Huang J, Huang S, Chai T, Shen J. Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: a systematic review and meta-analysis. Cardiovasc Ther. 2017;35(1):26–32.

    Article  CAS  PubMed  Google Scholar 

  • Zhao K, Yang M, Lu Y, et al. P2Y12 polymorphisms and the risk of adverse clinical events in patients treated with clopidogrel: a meta-analysis. Drug Res (Stuttg). 2019;69(1):23–31.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China

    Xiaoyan Nie & Xinyi Zhang

  2. Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA

    Christine Y. Lu

Authors
  1. Xiaoyan Nie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinyi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christine Y. Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaoyan Nie .

Editor information

Editors and Affiliations

  1. Medicines and Healthcare, Department of Pharmacy, University of Huddersfield, Huddersfield, UK

    Zaheer-Ud-Din Babar

Section Editor information

  1. Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA

    Christine Y. Lu

  2. Taipei Medical University, Taipei, Taiwan

    Jason Hsu

  3. International Ph.D. Program in Biotech and Healthcare Management, College of Management, Taipei Medical University, Taipei, Taiwan

    Rachele Hendricks-Sturrup

  4. Duke-Margolis Center for Health Policy, Washington, DC, USA

    Jason Hsu

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Nie, X., Zhang, X., Lu, C.Y. (2023). Evidence on the Impact of Pharmacogenetics to Treat and Manage Cardiovascular Diseases. In: Babar, ZUD. (eds) Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy. Springer, Cham. https://doi.org/10.1007/978-3-030-64477-2_147

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-64477-2_147

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-64476-5

  • Online ISBN: 978-3-030-64477-2

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation